Skip Navigation


NDT Advance Access originally published online on December 6, 2006
Nephrology Dialysis Transplantation 2007 22(2):316-318; doi:10.1093/ndt/gfl720
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/2/316    most recent
gfl720v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cozzolino, M.
Right arrow Articles by Brancaccio, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cozzolino, M.
Right arrow Articles by Brancaccio, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Lanthanum carbonate—new data on parathyroid hormone control without liver damage

Mario Cozzolino and Diego Brancaccio

Renal Division, University of Milan, S. Paolo Hospital, Milan, Italy

Correspondence and offprint requests to: Mario Cozzolino, MD, PhD, Renal Division, S. Paolo Hospital, University of Milan, Via A. di Rudinì, 8 – 20142 – Milan – Italy.Email: mariocozzolino@hotmail.com

Keywords: chronic kidney disease; lanthanum carbonate; phosphate; phosphate binders; secondary hyperparathyroidism

The first 10% of the full text of this article appears below.

Recent investigations have provided conclusive evidence that abnormalities in mineral and bone metabolism are associated with increased cardiovascular (CV) morbidity and mortality in chronic kidney disease (CKD) patients [1,2]. In fact, elevated serum phosphate (P) levels play an important role in the pathogenesis of secondary hyperparathyroidism (SHPT) [3]. Recent studies have shown the molecular mechanisms by which P may regulate parathyroid (PT) function. Within 2 weeks after 5/6 nephrectomy (Nx) in rats, uraemia-induced mitotic activity is further enhanced by high dietary P, but prevented by P-restriction [4,5]. In contrast to the mitogenic effects of hyperphosphataemia, low dietary P appears to counteract . . . [Full Text of this Article]



   The dream for every nephrologist is to control serum P-levels in CKD patients, using P-binders with no side effects. Can this dream become a reality?
 


   What do we know about the physiopathology of SHPT and use of P-binder?
 


   When we think of the potential side effects of lanthanum carbonate, should we consider liver ‘toxicity’, ‘deposition’, ‘accumulation’ or ‘handling’?
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats
Iddo Z. Ben-Dov, Orit Pappo, Miri Sklair-Levy, Hillel Galitzer, Yaron Ilan, Tally Naveh-Many, and Justin Silver
NDT 2007 22: 362-368. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Cozzolino and D. Brancaccio
Reply--Lanthanum hepatotoxicity-debate
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1789 - 1789.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. Lacour, I. G. Nikolov, N. Joki, and T. B. Drueke
Lanthanum carbonate, body lanthanum accumulation and potential liver toxicity
Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1788 - 1789.
[Full Text] [PDF]